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تفاعل خلل التوتُّر العضلي احلاد بعد جرعة قياسية للكلوروكني لعالج 
املالريا غري املعقدة
اأولو�شيجون بو�شاري، جوزيف فادير، �شيغان اجبوال، اولو�شيجون جربائيل، اأواليد اليجبيد، يو�شف اأوالدو�شو
ر الع�شلي احلاد  هو من االآثار خارج الهرمية التي حتدث عادة بعد ا�شتخدام جمموعة متنوعة من االأدوية اأو  امللخ�س: تفاعل خلل التوتُّ
العوامل املثرية للتوتر غري اأدوية الذهان.هنا نعر�س حالة رجل يبلغ من العمر 54 عاما نقل اإىل امل�شت�شفى بعد 10 �شاعات من ارتعا�س 
الع�شالت حول العينني والوجه والرقبة بعد تناول اجلرعة االأوىل عن طريق الفم من فو�شفات الكلوروكني )1غم ] 600 ملغ]( و�شفت لعالج 
املالريا الغري معقدة. اأعطي املري�س الديازيبام يف الوريد )10 ملغ( تلتها 10 ملغ من الديازيبام عن طريق الفم 3 مرات يف اليوم. حت�ّشنت 
االأعرا�س يف غ�شون 30 دقيقة من العالج، وخرج املري�س بعد 14 �شاعة بعد ال�شفاء الكامل.
ر الع�شلي احلاد؛ املال ريا؛ الكلوروكني؛ التناول عن طريق الفم؛ تقرير حالة؛ نيجرييا. مفتاح الكلمات: رد فعل؛ خلل التوتُّ
abstract: Acute dystonic reactions (ADR) are extrapyramidal effects that usually occur after the initiation of a 
wide variety of drugs or triggering factors besides neuroleptics. We report the case of a 54-year-old man who was 
admitted with an approximately 10-hour history of muscle twitching around the eyes, face and neck after he took 
the first dose of oral chloroquine phosphate (1 g [600 mg base]) prescribed for uncomplicated malaria. He was given 
intravenous diazepam (10 mg statum) followed by 10 mg of oral diazepam 3 times a day. The symptoms improved 
within 30 minutes of treatment, and he was discharged 14 hours later after a complete recovery.
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Acute dystonic reactions (ADR) are extrapyramidal side effects (EPSE) that usually occur after the initiation or a rapid 
increase in the dose of neuroleptic drugs.1 However, 
the reactions may occur with a wide variety of drugs 
or triggering factors besides neuroleptics.2,3 ADRs 
are characterised by the intermittent spasmodic 
or sustained involuntary contractions of muscles 
in the face, neck, trunk, pelvis and extremities.4 
They are often not life-threatening, but can cause 
great discomfort, producing significant anxiety and 
distress for patients, and may seriously disturb the 
relationship between the doctor and the patient.5
Chloroquine (CQ), a 4-aminoquinoline drug 
used for both the prevention and treatment of 
malaria, was discovered in 1934 and introduced into 
clinical practice in 1947.5 It has been largely replaced 
by the newer artemisinin-based combination 
therapy (ACT) as the first line of treatment for 
uncomplicated malaria due to Plasmodium 
falciparum. This is because of the emergence and 
spread of resistant strains through East and West 
Africa, Southeast Asia, and South America.5–8 
However, in some African countries there have 
been reports of a rapid decline in the frequency of 
resistance to CQ after its withdrawal, to the point 
where the drug is now once again considered to be 
effective.9–11 Thus, CQ still remains a frequently used 
drug in the treatment of uncomplicated malaria in 
sub-Saharan Africa. Given its low cost and wide 
availability, its occasional use in some autoimmune 
disorders, and current evaluation for new potential 
utilisations, CQ may remain in clinical use for a 
long time.12–14
Extrapyramidal syndrome (EPS) following CQ 
therapy has been reported in the past.15,16 However, 
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in our setting, CQ-induced ADR is very rare. This 
case report describes an occurrence of ADR in a 
middle-aged man after commencing a standard 
dose of oral CQ phosphate for parasitologically-
confirmed uncomplicated malaria.
Case Report
A 54-year old man was brought to the emergency 
room (ER) of the Federal Medical Centre, Ido-
Ekiti, Nigeria, with a complaint of involuntary 
muscle twitching around the eyes, face and neck 
which had started approximately 10 hours prior 
to presentation. He was experiencing difficulty in 
speaking and an abnormal posturing of the neck. 
There was no fever, dizziness, altered consciousness, 
photophobia or weakness of the limbs. He had 
been diagnosed with parasitologically-confirmed 
uncomplicated malaria about 18 hours previously 
and had immediately been given oral CQ phosphate 
BP (1 g CQ phosphate [600 mg base]) to be followed 
by 500 mg (300 mg base) at 6, 24 and 48 hours. 
The presenting complaint had started within 8 
hours of the first dose of CQ. He was not on any 
other drugs, food or herbal preparations. There 
was no past history of similar complaints or of any 
transient ischaemic attack, and he had neither a 
family history of dystonia nor a history of alcohol 
ingestion, cigarette smoking or use of illicit drugs 
such as cocaine.
A general examination revealed an anxious 
middle-aged man with facial muscle twitching 
and facial grimace. Other aspects of the general 
examination were unremarkable. A central nervous 
system examination showed a fully-conscious man 
who was well-oriented in time, place and person. 
There were neither signs of meningeal irritation nor 
asterixis. There was no cognitive impairment and no 
cranial nerve palsy. Deep tendon reflexes and tones 
were also normal. All other systems were grossly 
normal. All baseline investigations, which included 
complete blood counts, serum electrolytes, urea 
and basic urea nitrogen, liver enzymes and function 
tests, random and fasting blood glucose, and a serum 
lipid profile, were within normal limits. His resting 
electrocardiogram was also normal. A peripheral 
blood smear study for malaria parasites by light 
microscopy of thick and thin stained blood showed 
trophozoite and schizont forms of P. falciparum.
A clinical diagnosis of ADR secondary to CQ 
was made. The drug was discontinued and the 
patient was treated with intravenous diazepam 
(10 mg statum followed by 10 mg oral diazepam 
three times a day). An intravenous access line 
was also secured and a maintenance dose of 
an intravenous infusion of isotonic saline was 
administered. The symptoms improved rapidly 
within 30 minutes of commencing treatment and 
the patient was discharged after about 14 hours of 
admission with complete recovery. He remained 
well at follow-up one week later.
Discussion
The therapeutic index for CQ is small.17 However, 
at a standard dose for malaria treatment, the 
common adverse effects include gastrointestinal 
problems, headaches, nightmares, blurring of 
vision and itching. An ADR due to the use of CQ 
is very rare and there is a paucity of data on it in 
the literature.18 Achumba et al. reported a case of 
ADR after a single dose of CQ in a postoperative 
patient and in the presence of metronidazole.19 
The reported case suggested that the ADR might 
have been an idiosyncratic reaction and probably 
potentiated by the metronidazole. In our case, the 
ADR also occurred after a single dose of CQ but 
in the absence of any other medications. Although 
ADRs occasionally are dose-related, they are more 
often idiosyncratic and unpredictable.19
For most drugs that often cause ADR, 
particularly the neuroleptics, the pathophysiology 
is a drug-induced alteration of dopaminergic-
cholinergic balance in the nigrostriatum. They 
produce ADR by a nigrostriatal dopamine D2 
receptor blockade, which results in an excess of 
striatal cholinergic output.20 The pathophysiological 
mechanism underlying CQ-associated ADR is 
not well-known. However, it has been linked to a 
reduction in forebrain catecholamine levels and 
an inhibition of neuronal calcium uptake.19 This 
hypothesis could be supported in part by the 
effectiveness of benzodiazepines in the reversal of 
CQ-associated ADR. A normal balance between 
dopamine and acetylcholine in the basal ganglia 
involves modulation from gamma aminobutyric 
acid (GABA)-containing striatonigral neurons. 
GABA-ergic neurons are inhibitory and antagonise 
excitatory dopaminergic neurons. Stimulation of 
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the benzodiazepine receptors coupled to GABA 
receptors via the chloride ion channel in the central 
nervous system facilitate GABA transmission with 
a consequent inhibitory effect of muscle hypertonia 
and tremors.19–22 
Conclusion
Although CQ-induced ADR is a very rare adverse 
effect, it can be confused with other medical 
conditions in the ER such as a seizure disorder or 
a transient ischaemic attack. A detailed history-
taking remains pivotal, particularly the medication 
history, which should be obtained from others if the 
patient is not able to speak. ADRs occur very rarely 
in CQ use; thus, its prophylaxis is unnecessary and 
also not feasible. However, the treatment is usually 
straightforward and nearly always effective.
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